secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0000950170-22-004851
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa reports Q4 2021 net loss $23.4M; cash $351.4M; on track for MRT-2359 IND mid-2022
--------------------------------------------------------------------------------

- Net loss Q4 2021 $23.4M vs $19.7M in Q4 2020; FY 2021 loss $74.0M vs $35.9M in 2020.
- Cash, cash equivalents and restricted cash $351.4M as of Dec 31, 2021, expected runway into late 2024.
- R&D expenses Q4 2021 $18.1M, up from $9.9M in Q4 2020; G&A expenses $5.3M vs $2.1M.
- IND filing for MRT-2359 (GSPT1 degrader) targeted mid-2022; CDK2 and NEK7 programs in lead optimization.
- Promoted Jullian Jones to CBO and Phil Nickson to General Counsel; partnered with Weizmann Institute on covalent chemistry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022004851/0000950170-22-004851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022004851/glue-20220329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer